27 May 2016

Loss-making Greenchip in share swap

Aim-listed Greenchip Investments, the bombed-out e-business backer-turned degradable plastic specialist, lost 473,500 in the six months to June and has agreed a near-350,000 share swap with the currently floating New Opportunities Investment Trust, writes Robert Tyerman.

Porter Ribb, who has replaced Malcolm Burne as executive chairman of Greenchip, says the company's net assets have increased from 1 million last year to 4.26 million following the reverse takeover of US degradable plastic innovator Programmable Life, though that figure includes goodwill of 4.1 million. Greenchip, which lost 502,100 in last year's first half and 579,200 for all of 2001, says commercial trials for the new products it has backed were initiated 'at a slower rate than the company would prefer' and blames 'global uncertainties'.

However, Ribb says Greenchip is 'in advanced discussions with an [unnamed] target acquisition' and expects to close the deal no later than next February, 'subject to financing and due diligence'. The company has, meanwhile, negotiated to swap 25 million of its own shares now languishing at 1p for 375,000 New Opportunities shares, valued at 1 each before the swap but, in fact, trading at 92.5p on their second day on the London Stock Exchange.

At a 92.5p New Opportunities price, the paper value of this deal is, thus, 347,000 rather than 375,000 although even that represents a hefty premium to the 250,000 market value of 25 million Greenchip at 1p in late 2000, they were more than 30p. Under the deal, Greenchip, which has replaced Grant Thornton with F.W.Smith Richies as auditor, cannot sell the New Opportunities shares for 90 days.

Cash Shells 2015

Published in September 2015 this annual research report provides a comprehensive overview of cash shells on the Main Market, AIM and PLUS landscape. Order your copy today

 

Superb investment toolkit for private investors

SharePad is the new web-based service from ShareScope. Easier to use and more powerful. Perfect for tablets, Macs and Windows PC. Covers ALL your investment requirements.

Growth Company Investor: free trial

Since 2008, our share tips outperformed the benchmark by 281%. Take a free trial and get access to our recommendations today. Start free trial now.

Directors' Pay on AIM 2015

The most comprehensive review of AIM directors' pay available, and this year includes a record sample of 1000+ AIM-quoted companies. The full report is available to order for £385 + VAT. Click here for more info

 

Latest small-cap and growth company news

Daily coverage of small-cap company stocks on London's junior markets AIM and PLUS, breaking news, stock research and latest share price information for investors. Full sector coverage with all the latest news on smaller listed companies, updated several times a day with financial reports, trading statements and links to further web resources.

Popular News

Latest News

Motif Bio and the ticking timebomb

The recently published O'Neill report on antimicrobial resistance shows it to be a ticking timebomb. Resistance to antibiotics raises the prospect of 10 million deaths a year by 2050. This is a big opportunity for AIM listed Motif Bio (AIM: MTFB).      

Make mine a double!

Fevertree Drinks (AIM: FEVR) has been one of the most spectacular new issues on AIM in recent years, rising 412 per cent from the float price in late 2014. Today’s trading update served to emphasise why the shares are doing so well and drove them up another 15 per cent.

Fox Marble might be worth the wait 

Fox Marble (AIM: FOX) has raised £2 million through a placing at 10p. The funds will be mainly used to complete its long-delayed marble processing factory in Kosovo. Fox has an exciting story but unfortunately is lagging way behind its original roadmap to profitability.

Business as usual at XL Media 

XL Media (AIM: XLM) has announced the result of its strategic review. I hope no one was holding their breath, because the conclusion is to carry on as usual! The good news is that trading is said to have ‘maintained its excellent start to 2016’.

A Quantum of solace

Quantum Pharma (AIM: QP.) committed the cardinal sin of overpromising and under-delivering during its first year on AIM. New products took longer to come through the regulatory process than expected, which caused downgrades and a share price collapse from a high of 172p last June to the current 58p. However results for the financial year which ended in January suggest the company is getting to grips with the problems in its Niche Pharmaceuticals division.

Elecosoft constructs a strategy for growth 

Elecosoft (AIM: ELCO) is a specialist software company serving architects and builders. It used to be a much larger business but sold out of its building materials businesses four years ago to focus on its software arm. The challenge now is to generate some revenue growth and move off a sales plateau which has been in place since then.

More News